Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) Equity Ratio (2019 - 2026)

Opus Genetics has reported Equity Ratio over the past 13 years, most recently at 0.69 for Q1 2026.

  • Quarterly Equity Ratio fell 751.63% to 0.69 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.69 through Mar 2026, down 751.63% year-over-year, with the annual reading at 0.31 for FY2025, 67.47% up from the prior year.
  • Equity Ratio was 0.69 for Q1 2026 at Opus Genetics, down from 0.31 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.94 in Q4 2022 and troughed at 0.69 in Q1 2026.
  • The 5-year median for Equity Ratio is 0.84 (2022), against an average of 0.6.
  • Year-over-year, Equity Ratio surged 67.47% in 2025 and then crashed 751.63% in 2026.
  • A 5-year view of Equity Ratio shows it stood at 0.94 in 2022, then decreased by 1.98% to 0.93 in 2023, then plummeted by 80.28% to 0.18 in 2024, then surged by 67.47% to 0.31 in 2025, then crashed by 324.67% to 0.69 in 2026.
  • Per Business Quant, the three most recent readings for IRD's Equity Ratio are 0.69 (Q1 2026), 0.31 (Q4 2025), and 0.17 (Q3 2025).